1119 related articles for article (PubMed ID: 25765966)
1. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
[TBL] [Abstract][Full Text] [Related]
2. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P
Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
[TBL] [Abstract][Full Text] [Related]
10. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.
Kiely M; Billard MN; Toth E; Zafack JG; Landry M; Skowronski DM; De Serres G
Vaccine; 2018 Oct; 36(45):6688-6694. PubMed ID: 30269915
[TBL] [Abstract][Full Text] [Related]
11. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
13. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
Thollot F; Scheifele D; Pankow-Culot H; Cheuvart B; Leyssen M; Ulianov L; Miller JM
Pediatr Infect Dis J; 2014 Dec; 33(12):1246-54. PubMed ID: 25037033
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S
Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054
[TBL] [Abstract][Full Text] [Related]
15. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
17. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N
Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442
[TBL] [Abstract][Full Text] [Related]
19. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
